← Oncology Approval Tracker

FDA DECISION ·

Lanreotide injection (first generic)

lanreotide acetate · InvaGen Pharmaceuticals

First generic approvalFirst genericGastroenteropancreatic neuroendocrine tumors and carcinoid syndrome
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

First generic of the referenced lanreotide depot injection, including adults with unresectable, well- or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors and adults with carcinoid syndrome. The product also has an acromegaly indication.

LAMPGEN ANALYSIS

Why it matters

The product is relevant to both disease control and symptom management for neuroendocrine tumors.

What research teams should watch

Verify the selected strength and deep subcutaneous administration, and record whether the goal is tumor control or rescue therapy reduction.

PRIMARY RECORDS

Sources